Company: IMRX
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001790340-25-000053
Chunk: 36

Company: Immuneering Corp
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 36
---
. The amounts actually paid to Dr. Zeskind, Dr. Hall and Mr. Bookman were approved at target based on the performance of our Company in 2024, as determined by the compensation committee. Specifically, the compensation committee considered, among other things, the successful conduct and rapid progress of the Phase 2a trial for IMM-1-104, resulting in proof of concept data in first-line pancreatic cancer; the initiation of dosing and completion of the dose escalation and evaluation cohorts in the Phase 1/2a clinical trial for IMM-6-415; additional funding secured in 2024 and early 2025; and continued progress on the Company’s pipeline.

#### Equity Compensation
Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive officers, including our named executive officers, or any formal equity ownership guidelines applicable to them, we believe that equity grants provide our executive officers with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executive officers and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature incentivizes our executive officers to remain in our employment during the vesting period. Accordingly, our compensation committee periodically reviews the equity incentive compensation of our executives, including our named executive officers, and from time to time may grant equity incentive awards to them in the form of stock options.

We typically grant stock option awards to each executive officer and employee upon the individual’s commencement of employment and make additional grants of stock option awards on an annual basis for retention purposes. Each option has an exercise price no less than the fair market value of our common stock on the date of grant, as determined under the Company’s 2021 Incentive Award Plan (the “2021 Plan”). During the fiscal year ended December 31, 2024, we granted stock options to each of our named executive officers, as shown in more detail in the “Outstanding Equity Awards at Fiscal Year End” table below.

Refer to “Corporate Governance — Long-Term Incentive Compensation Grant Practices” above for additional information regarding our equity grant practices.

#### Repricing of Designated Underwater Stock Options
On May 21, 2024 (the “Repricing Effective Date”), based upon the recommendation of our compensation committee, the Board approved an option repricing, in accordance with the 2021 Plan. The repricing applied to options to purchase shares of our Class A